Insights

Type

Select all that apply

Topic

Select all that apply

icons/content-types/video webinar

Presented by Pete Michels, Ph.D., Head of Global Fermentation, Curia Jose Luis Barredo, Ph.D., Director, Engineering Services, Curia Listen in as our experts discuss: A brief history of biocatalysis with a look at its current and futur...

icons/content-types/video webinar

Presented by Mark Wolf, Ph.D., Section Head, Medicinal Chemistry - Curia Doug Kitchen, Ph.D., Section Head, CADD, Medicinal Chemistry - Curia Listen in as our experts discuss: The importance of a strong hit-to-lead program in drug d...

icons/content-types/white paper white paper

The COVID-19 pandemic has brought the global interdependency of pharmaceutical supply chains into sharp focus, exposing weak links and re-igniting discussions around the value of reshoring production. The U.S. Food and Drug Administration (FDA) repor...

icons/content-types/video webinar

In vitro biochemical assays make possible the high throughput screening (HTS) of large compound libraries. A successful HTS campaign is typically viewed as one that identifies large numbers of diverse chemical series hits as potential starting points...

icons/content-types/article article

Xtalks spoke with Dr. Steef Boerrigter, a senior research scientist at AMRI and an expert at materials science. He has extensive experience with experimental screening technologies for polymorphs, salts and cocrystals and has developed computational...

icons/content-types/video webinar

Join AMRI, PCI Pharma Services, and Cardinal Health Regulatory Sciences for this three-part webinar series as we review this complex process and identify common challenges to commercialization. We will focus on what drug synthesis, clinical logistics...

icons/content-types/video webinar

The objective of this webinar is to address United States Pharmacopeia (USP) and FDA regulatory trends to demonstrate how to integrate various analytical tests into a robust program that addresses product integrity/compatibility throughout the produc...

icons/content-types/video webinar

Drug formulators should consider the physical properties of their products during pharmaceutical drug development. The physical properties of a solid drug substance are highly dependent on the solid form. It is critical to understand the solid form l...

icons/content-types/article article

From target discovery through launching a finished product to market, developing a new drug is a complex process which takes on average 10-15 years and costs around 2.6 billion dollars. Early on, this process often involves a high-throughput screenin...

icons/content-types/article article

With increasing antibiotic resistance observed amongst clinical isolates of Neisseria gonorrhoeae, the second most prevalent sexually transmitted bacterial disease in the United States, there is still a need for antimicrobial susceptibility testing...

icons/utility/left caret 1 icons/utility/right caret